Kala Pharmaceuticals, Inc. (KALA) Analysts See $-0.37 EPS; Och-ziff Capital Management Group (OZM) Has 1.07 Sentiment

January 14, 2018 - By olga

Analysts expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to report $-0.37 EPS on February, 6.After having $-0.56 EPS previously, Kala Pharmaceuticals, Inc.’s analysts see -33.93% EPS growth. The stock increased 12.64% or $1.75 during the last trading session, reaching $15.6. About 387,357 shares traded or 37.31% up from the average. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Och-Ziff Capital Management Group LLC is a publicly owned hedge fund sponsor. The company has market cap of $1.23 billion. The firm provides investment advisory services for its clients. It has a 34.87 P/E ratio. It primarily caters to institutional investors which include pension funds, fund-of-funds, foundations and endowments, firms and other institutions, private banks and family offices.

Analysts await Och-Ziff Capital Management Group LLC (NYSE:OZM) to report earnings on February, 21. They expect $0.26 earnings per share, up 2,500.00% or $0.25 from last year’s $0.01 per share. OZM’s profit will be $117.76 million for 2.62 P/E if the $0.26 EPS becomes a reality. After $0.07 actual earnings per share reported by Och-Ziff Capital Management Group LLC for the previous quarter, Wall Street now forecasts 271.43% EPS growth.

Stonerise Capital Management Llc holds 8.85% of its portfolio in Och-Ziff Capital Management Group LLC for 1.75 million shares. Glacier Peak Capital Llc owns 2.08 million shares or 7.62% of their US portfolio. Moreover, North Run Capital Lp has 5.75% invested in the company for 3.80 million shares. The Massachusetts-based Abrams Capital Management L.P. has invested 2.8% in the stock. Odey Asset Management Group Ltd, a United Kingdom-based fund reported 7.21 million shares.

The stock decreased 1.45% or $0.04 during the last trading session, reaching $2.72. About 383,736 shares traded. Och-Ziff Capital Management Group LLC (OZM) has declined 36.39% since January 14, 2017 and is downtrending. It has underperformed by 53.09% the S&P500.

Ratings analysis reveals 0 of Och-Ziff Capital’s analysts are positive. Out of 2 Wall Street analysts rating Och-Ziff Capital, 0 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. OZM was included in 2 notes of analysts from August 25, 2016. The rating was downgraded by Citigroup to “Sell” on Thursday, August 25. The firm has “Neutral” rating by JP Morgan given on Thursday, February 16.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle Mucus Penetrating Particles technology. The company has market cap of $382.53 million. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It currently has negative earnings. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>